Monitor the May 11 conference call for any safety or efficacy signals from the first three GBM patients. Positive interim data could provide a near-term catalyst, but given the tiny sample size and early stage, any price move is likely speculative and short-lived.
Price Chart
Executive Summary
Alpha Tau Medical Ltd. filed a 6-K on May 8, 2026, announcing a conference call to discuss interim clinical data from the first three patients treated in its REGAIN trial for recurrent glioblastoma. The filing is a routine update on early-stage clinical progress with no financial data or material corporate events disclosed.
Key Facts
- Conference call scheduled for May 11, 2026 at 8:30am ET to discuss interim data from first three patients in REGAIN trial.
- REGAIN trial is a U.S. study for recurrent glioblastoma not amenable to surgical resection, expected to enroll up to ten patients.
- No financial results, guidance, or material agreements were disclosed in the filing.
Financial Impact
No financial figures reported; pre-revenue clinical-stage company.
Risk Factors
- Interim data from only three patients is not statistically meaningful and may not predict final trial results.
- Alpha Tau has no approved products and relies on future funding; the 20-F notes significant losses and need for additional capital.
- Historical calibration shows prior high-score reports on DRTSW had negative T+20 outcomes, suggesting limited market reaction to clinical updates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-053597 |
| Document: ea028978302ex99-1.htm | 0001213900-26-053597 |
| Document: 0001213900-26-053597-index-headers.html | 0001213900-26-053597 |
| Document: 0001213900-26-053597-index.html | 0001213900-26-053597 |
| Document: 0001213900-26-053597.txt | 0001213900-26-053597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access